HTA as input to NICE guidance in England and Wales. Sarah Garner, Technical Adviser National Institute for Health and Clinical Excellence

Similar documents
NICE Charter Who we are and what we do

Assessment of e-health technology

RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO ACCESS TO MEDICAL TECHNOLOGIES IN WALES

Still Being NICE After 14 Years

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE

Issue date: October Guide to the multiple technology appraisal process

CUHK-HKU Joint Family Medicine Research Meeting

- Proposal for a Regulation on HTA- Ioana Siska, MD, PhD DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

Newborn Screening Programmes in the United Kingdom

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

Transforming the research environment in Wales. NHS R&D Forum 2014

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31

Section 2: Advanced level nursing practice competencies

Esteban de Manuel (Kronikgune) CareWell Project coordinator 30 September 2016, Bad Hofgastein, Austria

G-I-N 2016 conference report

Continuous Professional Development of Health Professionals European Context

- Proposal for a Regulation on HTA- DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

How NICE clinical guidelines are developed

Public Health Skills and Career Framework Multidisciplinary/multi-agency/multi-professional. April 2008 (updated March 2009)

Health Technology Wales

1. The Department funds R&D through two main routes:

NIHR Funding For further assistance with NIHR funding please contact the Protocol Development Service

Guy s and St. Thomas Healthcare Alliance. Five-year strategy

Pharmacist (Palliative Care) December 2014 Page 1

Medical Device Reimbursement in the EU, current environment and trends. Paula Wittels Programme Director

Health Technology Assessment (HTA) Good Practices & Principles FIFARMA, I. Government s cost containment measures: current status & issues

NHS QIS & NICE Advice. defi nitions & status

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

C. Agency for Healthcare Research and Quality

Generic Job Description Consultant Pharmacist. Job Purpose

Western Cape: Research strategy and way forward. Tony Hawkridge Director: Health Impact Assessment Western Cape Government: Health

ERN Assessment Manual for Applicants

abcdefghijklmnopqrstu

Initial education and training of pharmacy technicians: draft evidence framework

NIHR funding programmes. Twitter: NIHR YouTube: NIHRtv

Document: Report on the work of the High Level Group in 2006

SITUATION ANALYSIS OF HTA INTRODUCTION AT NATIONAL LEVEL. Instruction for respondents

Translational Research Strategic Plan Continuing the Mission of the Sisters of the Little Company of Mary

Corporate Induction: Part 2

BSAC STRATEGY ANTIMICROBIAL CHEMOTHERAPY BRITISH SOCIETY FOR

Post-Professional Doctor of Occupational Therapy Elective Track in Administration and Practice Management

Post-Professional Doctor of Occupational Therapy Elective Track in Aging

Innovation and Entrepreneurship in Higher Education: the European Institute of Innovation and Technology (EIT)

How to use NICE guidance to commission high-quality services

~ RESEARCH FUNDING UPDATE ~ Projects & Programmes 18 th November 2013

Report on Feasibility, Costs, and Potential Benefits of Scaling the Military Acuity Model

High Level Pharmaceutical Forum

NHS Innovation and Technology Payment

Over a number of years the Rotorua Te Arawa Lakes Programme has explored ways to improve lake water quality for the Rotorua Te Arawa Lakes.

Corso di Informatica Medica

Physician / Investigator. Over 40% of clinical trial data are entered into health record and EDC 1

Pharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA

North Herts Hospice Care Association. Job Description. Education and Practice Development Lead

Indicators and descriptors and how they can be used. Hanne Herborg Director R&D Danish College of Pharmacy Practice

MEMORANDUM OF UNDERSTANDING

Lorraine Stewart UNIPHE Project Co-ordinator

Health Technology Assessment (HTA)

ESF Peer Review Services

6 TH CALL FOR PROPOSALS: FREQUENTLY ASKED QUESTIONS

Developing. National Service Frameworks

Mutah University- Faculty of Medicine

THAMES VALLEY PRIORITIES COMMITTEE ETHICAL FRAMEWORK

Core Domain You will be able to: You will know and understand: Leadership, Management and Team Working

European network of paediatric research (EnprEMA)

Medical Technology Innovation: Driving efficiencies of healthcare systems

NIHR Funding Opportunities

Clinical Nurse Specialist - Quality & Research Dept of Anaesthesiology

Pre Assessment Policy. Trust Policy Forum March 2004

Tissue Viability Society. Strategy A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there...

DRAFT OPINION. EN United in diversity EN. European Parliament 2018/0018(COD) of the Committee on Industry, Research and Energy

MHRA response to the Independent Review on access to clinical advice and engagement with the clinical community in relation to medical devices

Medicines New Zealand

The PCT Guide to Applying the 10 High Impact Changes

MORTALITY REVIEW POLICY

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

Medicines Optimisation Strategy

Workshop Networking for Innovation under measure 16 in Rural Development Programmes October 2015 Tallinn, Estonia

Learning from adverse events. Learning and improvement summary

Knowledge for Healthcare Becoming Business Critical. Making it happen

ABMS Organizational QI Forum Links QI, Research and Policy Highlights of Keynote Speakers Presentations

Standards of Proficiency for Higher Specialist Scientists

NICE s Highly Specialised Technologies (HST) evaluation committee

Framework for Cancer CNS Development (Band 7)

NHS TAYSIDE MORTALITY REVIEW PROGRAMME

Data, analysis and evidence

Patient-Centred Decision Making with MCDA: Should We Be Trying to Quantify the Patient Voice for Use in HTA?

SANICADEMIA International Training Academy for health professionals

Grünenthal Norway AS - Methodological Note

SCOTTISH AMBULANCE SERVICE JOB DESCRIPTION

The Helsinki Manifesto We have to move fast, before it is too late.

Clinical Nurse Specialist - Research General Surgery

QUALITY COMMITTEE. Terms of Reference

Making Clinical Governance Work

Process and methods Published: 30 November 2012 nice.org.uk/process/pmg6

Item No. 9. Meeting Date Wednesday 6 th December Glasgow City Integration Joint Board Finance and Audit Committee

Majors with semester credit hours (SCH)

Post-Professional Doctor of Occupational Therapy Advanced Practice Track

Aintree University Hospital NHS Foundation Trust Corporate Strategy

Transcription:

HTA as input to NICE guidance in England and Wales Sarah Garner, Technical Adviser National Institute for Health and Clinical Excellence

What is NICE? The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.

NICE Centre for Public Health Excellence - public health interventions - public health programmes Centre for Health Technology Evaluation - technology appraisals - interventional procedures Centre for Clinical Practice - clinical guidelines

Technology appraisals Guidance on the clinical and cost effectiveness of specific new or existing medicines and treatments leading to recommendations on the appropriate use of the technology within the NHS. Pharmaceuticals Devices Diagnostics Procedures Health promotion tools

Key principles of NICE guidance development Focused questions Stakeholder input Independent robust evidence assessment Independent advisory committee Multiple perspectives Transparent process & decision making Genuine and public consultation Regular review

HTA

Appraisal Assessment

Assessment Clinical Effectiveness Cost Effectiveness Context

Appraisal Research Evidence Patient Experience Clinical Practice

Assessment Report Overview Consultee submissions Appraisal Assessment group response Consultee comments Expert input

The Process Scoping Submission Review Consultation Assessment Guidance Appraisal

www.nice.org.uk

HOW TO ENSURE THE POLICY RELEVANCE OF HTA VIEWS FROM THE GOVERNMENT PERSPECTIVE Kari Harno M.D. Ph.D. Chief Physician Hospital District of Helsinki and Uusimaa

FINNISH OFFICE FOR HTA Finohta - national domain for HTA focused on micro-level assessment publicly funded, level of autonomy HTA Research co-ordinator, facilitator and expert Dissemination of information clearinghouse 2

HTA STRATEGY 2006-2009 Guiding principles independence reliability decision support viability collaboration methodology support Focus groups health policy makers health care providers Aims for HTA in policy decisions preset HTA targets have been met number of HTA reports enhances application of HTA information increases know-how of HTA improves 3

RESEARCH TO POLICY 1/2 thinkingbeyondefficacy evaluation of effectiveness profiling the problem and managed uptake of medical methods information dissemination catalyst for technology adoption support for implementation 4

RESEARCH TO POLICY 2/2 NEXT STEPS forecasting the impact of emerging technologies early warning system for ripple effects EB implementation strategies self-assessment of Finohta HTA related academic positions cross-border collaboration for planning HTA 5

MORE INFORMATION www.stakes.fi/finohta 6

Health decisionmaking in Germany

Health care decision making Evidence Values Resources Muir Gray 1997

Self Administration of Health Care in Germany Ministry of Health Legal supervision Federal Joint Committee Patients, Physicians, Sickness Insurance Funds Decision making Institute for Quality and Efficiency in Health Care Production of evidence based information http://www.g-ba.de

Effects and benefits Mortality Morbidity Health-related quality of life Use of health care recourses Patient satisfaction

Grades of Evidence Pathophysiologic studies Description of cases Cross-sectional studies Case control studies Cohort studies Randomized controlled trials Error

Evidence based decision making Pathophysiologic studies Description of cases Available Evidence Cross-sectional studies Case control studies Cohort studies Sufficient Evidence Randomized controlled trials

Evidence based decision making The gap between available and sufficient evidence must be put into relation to Nature and severity of the disease. Magnitude of the therapeutic effect. Availability of alternatives.

Segreteria Regionale Sanità e Sociale Dr. Giancarlo Ruscitti European Health Forum Gastein, 2006

PRESENT SITUATION Increasing health care needs BUT limited available resources Need to assess: Appropriateness of diagnostic and therapeutic procedures Technologies to be used in health care institutions Organization models to best allocate scarce resources Primary role of HTA

TECHNOLOGY ASSESSMENT The assessment on a HEALTH CARE INNOVATION must consider a number of elements: It must guarantee effectiveness when dealing with a target problem ; It must be safe ; No-one should risk being harmed by the use of it; It must show a good patient compliance ; Its solutions must satisfy the priorities defined at the public level ; Its cost must not exceed its value ; It must be compatible with the budget available. In theory, these are the variables at play. In practice, they are complicated by the possible clash between different actors in the health sector Importance of NETWORKS at local, regional, national and european level

REGIONAL CONTEXTS Regions achieving objectives: High technology management (within the current scenario of lack of scientific evidence) Medical devices management Improvement of health care performance through advanced and coherent information technologies which enable health workers and professionals to meet the needs of patients by optimising the organization and sharing of information (i.e. e-government and e- health) Management of pharmacological innovation

THE VENETO REGION CONTEXT Veneto achieving objectives: 1. High technology management 2. Improvement of health care performance through computerized technology 3. Mangement of pharma innovation 4. Creation of a multidisciplinary group for the dissemination of the principles and methodology of HTA in the regional health service 5. Cross border cooperation in HTA

1. HIGH TECHNOLOGY MANAGEMENT After the national law arrangement on competencies (D.Lgs. 502/92 and D.Lgvo 229/99) VENETO REGION ULSS Governance task on the health care planning, guidance and control Management task in obedience to regional guidelines INVESTMENT PLANNING in HEALTH CARE field is a REGIONAL CHOICE that requires health care EXPENDITURE GOVERNANCE and available resources BEST UTILIZATION.

1. HIGH TECHNOLOGY MANAGEMENT PHASES for the decision of financing effective investment in the social and health care sector PROJECT PROPOSITION: LHU and Hospital proposals are presented to the Regional government; PROJECT SELECTION: proposals are selected according to economic viability, financial feasibility and sustainability criteria, in a overall multi-year frame; PROJECT FINANCING: projects are financed according to the available resources; PROJECT REALIZATION: projects are realized and subsequently examined by the regional government.

2. THE IMPROVEMENT OF HEALTH CARE PERFORMANCE THROUGH COMPUTERIZED TECHNOLOGIES The introduction of TELEMEDICINE applications requires: the re-organization of internal processes the streamlining of human and technological resources the full support of governing bodies

2. THE IMPROVEMENT OF HEALTH CARE PERFORMANCE THROUGH COMPUTERIZED TECHNOLOGIES HEALTH OPTIMUM Project Financed by European Commission, Regione Veneto Project Leader Sharing experiences among different LHUs, Regions, Countries Supporting partners for technical and organizational aspectss Specialties covered: - Neurosurgical Teleconsultation - Telelaboratory applied to HomeCare All information produced by the two strands converge in a PATIENT BOOKLET

3. MANAGEMENT OF THE PHARMA INNOVATION PHARMA EXPENDITURE Up to a 10% annual increase SUSTAINABLE EXPENDITURE Up to a 3-4% annual increase To find a balance between sustainable expenditure and predicted consumption and to promote an effective use of drugs, Veneto Region boasts of: The Regional Hospital Manual of Pharmaceuticals The Regional Information Network The Regional Network of Pharmaceutical Surveillance The Regional Network of Ethical Committees

4. CREATION OF A MULTIDISCIPLINARY GROUP FOR THE DISSEMINATION OF THE PRINCIPLES AND METHODOLOGIES OF HTA Operates on 2 main fronts REGIONAL Setting up of a Technical Group which supports HTA and includes all kind of professional categories (doctors, economists, engineers, clinicians, statisticians ) NATIONAL Development of a national HTA network (in which Veneto partecipates through LHUs) to identify the minimum structural, organizational and functional prerequisites for the launching of a HTA programme on a Regional and LHU level, within the NHS

5. HTA IN CROSS-BORDER COOPERATION Veneto Region has begun a process of information sharing in the area of technology assessment with the Regions of Friuli Venezia Giulia and Carinthia. This type of collaboration will be implemented on a wider scale in the Euroregione project.